Scott J Antonia

List of Publications by Year in Descending Order

81 papers	28,350 citations	43 h-index	83 g-index
83 ext. papers	34,497 ext. citations	11 avg, IF	6.29 L-index

#	Paper	IF	Citations
81	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101308	2.2	42
80	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. *Lung Cancer*, **2022**, 166, 84-93	5.9	0
79	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma **2022**, 10, e003956		0
78	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. *Future Oncology*, **2021**, 17, 1165-1184	3.6	2
77	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. *Journal of Thoracic Oncology*, **2021**, 16, 860-867	8.9	118
76	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). *Clinical Lung Cancer*, **2021**, 22, 549-561	4.9	4
75	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors **2021**, 9,		11
74	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 425-435	4	8
73	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). *Lung Cancer*, **2021**, 151, 30-38	5.9	9
72	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. *Annals of Surgical Oncology*, **2021**, 28, 3501-3510	3.1	3
71	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 419-427	8.9	9
70	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nature Medicine*, **2021**, 27, 1410-1418	50.5	31
69	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 661-674	13.4	205
68	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. *Cancer Medicine*, **2020**, 9, 225-237	4.8	9
67	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. *Journal of Thoracic Oncology*, **2020**, 15, 288-293	8.9	203
66	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *Journal of Thoracic Oncology*, **2020**, 15, 426-435	8.9	96
65	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 1794-1806	8.9	47

64	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. *European Journal of Cancer*, **2019**, 109, 154-161	7.5	42
63	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. *Lancet Oncology, The*, **2019**, 20, 1395-1408	21.7	149
62	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncology*, **2019**, 5, 1411-1420	13.4	216
61	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2019**, 20, 1670-1680	21.7	67
60	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2019**, 25, 6623-6632	12.9	59
59	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 517-527	7.4	18
58	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. *Journal of Thoracic Oncology*, **2019**, 14, 237-244	8.9	163
57	Durvalumab in Stage III Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2018**, 378, 869-879	59.2	21
56	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell*, **2018**, 33, 843-852.e4	24.3	525
55	Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. *Patient Education and Counseling*, **2018**, 101, 703-710	3.1	6
54	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. *Cancer Cell*, **2018**, 33, 853-861.e4	24.3	471
53	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. *Tuberculosis and Respiratory Diseases*, **2018**, 81, 29-41	3.2	12
52	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. *JNCI Cancer Spectrum*, **2018**, 2, pky021	4.6	73
51	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. *European Journal of Cancer*, **2018**, 101, 201-209	7.5	36
50	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) **2018**, 6, 75		107
49	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *New England Journal of Medicine*, **2018**, 379, 2342-2350	59.2	1336
48	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1853-1862	7.4	11
47	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. *Expert Opinion on Biological Therapy*, **2017**, 17, 305-312	5.4	34

46	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. *Journal of Neuro-Oncology*, **2017**, 133, 331-338	4.8	77
45	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncology, The*, **2017**, 18, 31-41	21.7	605
44	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. *Neoplasia*, **2017**, 19, 530-536	6.4	46
43	Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment **2017**, 5, 54		26
42	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2017**, 377, 1919-1929	59.2	2034
41	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. *Lancet Oncology, The*, **2017**, 18, 1261-1273	21.7	266
40	A Bayesian pick-the-winner design in a randomized phase II clinical trial. *Oncotarget*, **2017**, 8, 88376-88385	5.3	2
39	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncology, The*, **2016**, 17, 883-895	21.7	783
38	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. *Clinical Cancer Research*, **2016**, 22, 4119-32	12.9	183
37	Immunotherapy: Beyond Anti‐PD-1 and Anti‐PD-L1 Therapies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, e450-e458	7.1	13
36	A phase I study of indoximod in patients with advanced malignancies. *Oncotarget*, **2016**, 7, 22928-38	3.3	108
35	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e450-8	7.1	22
34	The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. *BMC Cancer*, **2016**, 16, 176	4.8	57
33	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. *Expert Review of Anticancer Therapy*, **2016**, 16, 903-10	3.5	5
32	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncology, The*, **2015**, 16, 257-65	21.7	1050
31	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2004-12	2.2	859
30	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2015**, 373, 1627-39	59.2	5964
29	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. *Journal of Thoracic Oncology*, **2015**, 10, 974-84	8.9	86

28	A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. *Breast Cancer: Targets and Therapy*, **2015**, 7, 389-97	3.9	7
27	Immuno-oncology combinations: a review of clinical experience and future prospects. *Clinical Cancer Research*, **2014**, 20, 6258-68	12.9	76
26	Genetically Modified Dendritic Cell Vaccines for Solid Tumors **2014**, 273-282		
25	Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. *OncoImmunology*, **2013**, 2, e23428	7.2	59
24	A new role for NFB in immunosurveillance and its implications for cancer immunotherapy. *OncoImmunology*, **2013**, 2, e25963	7.2	3
23	Immunotherapy in lung cancer: "b7-bombers" and other new developments. *Seminars in Respiratory and Critical Care Medicine*, **2013**, 34, 810-21	3.9	6
22	Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. *Cancer Biology and Therapy*, **2013**, 14, 860-8	4.6	63
21	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. *Journal of Clinical Oncology*, **2013**, 31, 3002-3002	2.2	38
20	Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.. *Journal of Clinical Oncology*, **2013**, 31, TPS3112-TPS3112	2.2	2
19	Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 924-32	4	92
18	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*, **2012**, 366, 2443-54	59.2	8684
17	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. *Anticancer Research*, **2011**, 31, 3193-204	2.3	25
16	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. *Cancer Biology and Therapy*, **2010**, 10, 983-93	4.6	111
15	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. *Expert Opinion on Biological Therapy*, **2010**, 10, 983-91	5.4	83
14	Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. *Journal of Immunotherapy*, **2008**, 31, 72-80	5	57
13	A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. *Annals of Surgical Oncology*, **2007**, 14, 869-84	3.1	41
12	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. *Journal of Clinical Oncology*, **2007**, 25, 876-83	2.2	382
11	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 878-87	12.9	336

10	A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. *Journal of Surgical Research*, **2005**, 125, 173-81	2.5	16
9	Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *Journal of Clinical Investigation*, **2004**, 114, 280-90	15.9	533
8	Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. *Laboratory Investigation*, **2003**, 83, 1457-66	5.9	104
7	Cell-based immune therapy for metastatic renal cancer. *Expert Review of Anticancer Therapy*, **2003**, 3, 837-49	3.5	2
6	Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. *International Journal of Cancer*, **2002**, 101, 151-5	7.5	309
5	Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. *Science*, **2002**, 297, 1867-70	33.3	861
4	Phase I Trial of a B7-1 (CD80) Gene Modified Autologous Tumor Cell Vaccine in Combination With Systemic Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. *Journal of Urology*, **2002**, 167, 1995-2000	2.5	98
3	B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. *World Journal of Urology*, **2000**, 18, 157-63	4	12
2	Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding. *Clinical Immunology and Immunopathology*, **1989**, 53, 281-96		5
1	Adherence of tumor cells to endothelial monolayers: inhibition by lymphokines. *Cellular Immunology*, **1985**, 95, 247-57	4.4	4